Statement attributable to:
Ryan D. Mire, MD, FACP
President, ACP
Washington, D.C. June 23, 2022 – The ¹Ü¼ÒÆÅÐÄË®ÂÛ̳ (ACP) is pleased that the Food and Drug Administration (FDA) will ban JUUL Labs Inc. from selling, distributing, and marketing e-cigarette and electronic nicotine delivery system (ENDS) products across the nation.
ACP has long advocated for regulation of these products, and continues to urge the FDA and Congress to act to hamper the adverse effects of nicotine use, including banning flavored tobacco products.
As physicians, we know the danger that nicotine products and smoking present to our patients’ health. It is critically important that we confront the worsening epidemic of nicotine addiction. More than 5 million children now use e-cigarettes, including over 1 in 4 high school students. Youth e-cigarette use and nicotine addiction leads to increased risk of cigarette use over the course of an individual’s life. The banning of JUUL e-cigarettes and other flavored ENDS products is a critical step to improving public safety and potentially reducing the risk of young people and non-smokers beginning to use nicotine products. ACP will continue to press regulators and legislators to act in the best interest of public health.
Contact: Laura Baldwin, (215) 351-2668, lbaldwin@acponline.org
***
About the ¹Ü¼ÒÆÅÐÄË®ÂÛ̳
The is the largest medical specialty organization in the United States with members in more than 145 countries worldwide. ACP membership includes 161,000 internal medicine physicians (internists), related subspecialists, and medical students. Internal medicine physicians are specialists who apply scientific knowledge and clinical expertise to the diagnosis, treatment, and compassionate care of adults across the spectrum from health to complex illness. Follow ACP on , , and .